KCA
WHWK

KVP Capital Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

KVP Capital Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.92M Hold
2,165,997
– – 7.28% 2
2026
Q1 		$7.47M Hold
2,165,997
– – 5.58% 3
2025
Q4 		$5.24M Buy
+2,165,997
New +$4.97M 5.07% 5

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

KVP Capital Advisors's WHWK Position: Q2 2026 in Review

KVP Capital Advisors held its Whitehawk Therapeutics (WHWK) position steady in Q2 2026 at 2,165,997 shares worth $9.92M. The position accounts for 7.28% of the portfolio, ranked #2.

KVP Capital Advisors first reported a position in WHWK in Q4 2025 and has held it in 3 quarters since. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • KVP Capital Advisors held 2,165,997 shares of Whitehawk Therapeutics worth $9.92M as of Q2 2026.
  • KVP Capital Advisors left its Whitehawk Therapeutics share count unchanged in Q2 2026.
  • Whitehawk Therapeutics made up 7.28% of KVP Capital Advisors's portfolio in Q2 2026, its #2 holding.
  • KVP Capital Advisors first reported a position in Whitehawk Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.